Biomarin Pharmaceutical Inc. (BMRN)
Summary
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Biomarin Pharmaceutical Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 4,512 | $271,157.64 | $266,120.47 | -$5,037.17 | -1.86% |
 Dodge & Cox Dodge & Cox Funds | 14.96M | $1.19B | $882.07M | -$307.46M | -25.85% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 3,000 | $178,290 | $176,941.8 | -$1,348.2 | -0.76% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 74 | $6,751.64 | $4,370.8 | -$2,380.84 | -35.26% |
| BG Bart Gancher Intech Investment Management LLC | 33,497 | $1.93M | $1.98M | $51,076.25 | 2.65% |
Biomarin Pharmaceutical Inc. (BMRN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biomarin Pharmaceutical Inc. ever had a stock split?
Biomarin Pharmaceutical Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Alexander Hardy CEO | NASDAQ (NGS) Exchange | 09061G101 CUSIP |
| BR Country | 3,221 Employees | - Last Dividend | - Last Split | 23 Jul 1999 IPO Date |
Overview
BioMarin Pharmaceutical Inc. is a distinguished entity focused on the development and commercialization of innovative therapies for individuals facing serious and life-threatening rare diseases and medical conditions. Since its establishment in 1996, the company has dedicated its efforts towards providing groundbreaking treatments for patients with limited therapeutic options. Headquartered in San Rafael, California, BioMarin operates on a global scale, serving specialty pharmacies, hospitals, and non-U.S. government agencies, in addition to engaging with distributors and pharmaceutical wholesalers across the United States, Europe, Latin America, and other international territories. Through its strategic license and collaboration agreements with notable entities like Sarepta Therapeutics, Ares Trading S.A., and Catalyst Pharmaceutical Partners, Inc., BioMarin seeks to expand its impact and reach within the rare disease community.
Products and Services
- Vimizim: An enzyme replacement therapy aimed at treating mucopolysaccharidosis (MPS) IV type A, a rare lysosomal storage disorder. Vimizim provides critical enzyme supplementation to address the underlying cause of the condition.
- Naglazyme: A recombinant form of N-acetylgalactosamine 4-sulfatase designed for patients with MPS VI. This product exemplifies BioMarin's commitment to addressing unmet medical needs within the lysosomal storage disorder community.
- Kuvan: A proprietary synthetic oral form of 6R-BH4, Kuvan stands as a cornerstone therapy for individuals with phenylketonuria (PKU), a genetic metabolic disease. It aids by modulating the phenylalanine hydroxylase enzyme, thereby managing phenylalanine levels in the body.
- Palynziq: This product is a PEGylated recombinant phenylalanine ammonia lyase enzyme administered through subcutaneous injection. It is aimed at reducing blood phenylalanine concentrations in patients, showcasing BioMarin's innovation in enzyme replacement therapies.
- Brineura: A recombinant human tripeptidyl peptidase 1 treatment for patients suffering from ceroid lipofuscinosis type 2, a form of Batten disease. Brineura underscores BioMarin's dedication to tackling neurodegenerative disorders.
- Voxzogo: A once-daily injection analog of c-type natriuretic peptide intended for achondroplasia patients. Voxzogo is a pioneering treatment aimed at addressing the root cause of dwarfism by promoting bone growth.
- Aldurazyme: Designed to be identical to the naturally occurring human enzyme alpha-L-iduronidase, Aldurazyme is a purified protein for MPS I patients. It represents a fundamental approach to treating lysosomal storage disorders by supplementing missing or deficient enzymes.
- Roctavian: Currently in development, Roctavian utilizes an adeno associated virus vector for patients with severe hemophilia A. This gene therapy represents BioMarin's cutting-edge research efforts to provide long-term solutions for hereditary blood disorders.
